GRAIL Overview

  • Founded
  • 2015
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 700
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $8B
Latest Deal Amount

GRAIL General Information

Description

Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection, enabling doctors to get products for the early detection of cancer.

Contact Information

Website
www.grail.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Parent Company
Primary Office
  • 1525 O'Brien Drive
  • Menlo Park, CA 94025
  • United States
+1 (833) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GRAIL Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 18-Aug-2021 $8B 000 000 Completed Generating Revenue
5. IPO 17-Mar-2021 00000 Cancelled Generating Revenue
4. Later Stage VC (Series D) 06-May-2020 00000 000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 21-May-2018 00000 00.000 00.00 Completed Generating Revenue
2. Later Stage VC (Series B) 22-Nov-2017 $1.21B $1.31B 00.000 Completed Generating Revenue
1. Later Stage VC (Series A) 08-Jan-2016 $100M $100M 00000 Completed Startup
To view GRAIL’s complete valuation and funding history, request access »

GRAIL Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 0.00
Series B 309,256,591 $0.001000 $4.01 $4.01 1x $4.01 41.14%
Series A 85,000,000 $0.001000 $1 $1 1x $1 11.31%
To view GRAIL’s complete cap table history, request access »

GRAIL Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator a life sciences company created to detect cancer early when it can be cured. The company's the power of high-in
Biotechnology
Menlo Park, CA
700 As of 2021
000
00 0000-00-00
000000&0 000

00000 00

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000 000000000
Madison, WI
0000 As of 0000
00.000
00000000 00.000

00000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000000000 000000000
Seattle, WA
00 As of 0000
0000
000 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GRAIL Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exact Sciences Formerly VC-backed Madison, WI 0000 00.000 00000000 00.000
00000000 Venture Capital-Backed Seattle, WA 00 0000 00000000000 0000
0000000 0000000000 Venture Capital-Backed Beverly, MA 00 000.00 000000 0 000.00
0000000000 0000000 Formerly VC-backed Cambridge, MA 0000 00000 00000000000
000000000 Venture Capital-Backed Siena, Italy 00 0000000000 0
You’re viewing 5 of 32 competitors. Get the full list »

GRAIL Patents

GRAIL Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210313006-A1 Cancer classification with genomic region modeling Pending 31-Mar-2020 0000000000
US-20210310075-A1 Cancer classification with synthetic training samples Pending 30-Mar-2020 0000000000
US-20210285042-A1 Systems and methods for calling variants using methylation sequencing data Pending 28-Feb-2020 000000000
US-20210292845-A1 Identifying methylation patterns that discriminate or indicate a cancer condition Pending 28-Feb-2020 0000000000
US-20210238668-A1 Biterminal dna fragment types in cell-free samples and uses thereof Pending 08-Jan-2020 C12Q1/6869
To view GRAIL’s complete patent history, request access »

GRAIL Executive Team (14)

Name Title Board Seat Contact Info
Gautam Kollu Chief Commercial Officer
Satnam Alag Ph.D Senior Vice President, Software Engineering & Chief Security Officer
Joshua Ofman MD Chief Medical Officer & External Affairs
Jeffrey Huber Co-Founder & Vice Chairman
Aaron Freidin Senior Vice President, Finance
You’re viewing 5 of 14 executive team members. Get the full list »

GRAIL Board Members (14)

Name Representing Role Since
Brook Byers Ph.D Self Board Member 000 0000
Catherine Friedman Self Chairman 000 0000
Hal Barron MD Self Board Member 000 0000
Jeffrey Huber GRAIL Co-Founder & Vice Chairman 000 0000
Kaye Foster GRAIL Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

GRAIL Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GRAIL Former Investors (38)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Ally Bridge Group PE/Buyout Minority 000 0000 000000 0
Amazon.com Corporation Minority 000 0000 000000 0
Amino Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 38 investors. Get the full list »

GRAIL Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 31-May-2017 0000000000 Biotechnology 0000000 0
To view GRAIL’s complete acquisitions history, request access »